RXRX Annual CFI
-$10.23 M
-$203.48 M-105.29%
31 December 2023
Summary:
As of January 23, 2025, RXRX annual cash flow from investing activities is -$10.23 million, with the most recent change of -$203.48 million (-105.29%) on December 31, 2023. During the last 3 years, it has fallen by -$1.49 million (-17.03%). RXRX annual CFI is now -105.29% below its all-time high of $193.25 million, reached on December 31, 2022.RXRX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RXRX Quarterly CFI
-$4.56 M
-$380.00 K-9.09%
30 September 2024
Summary:
As of January 23, 2025, RXRX quarterly cash flow from investing activities is -$4.56 million, with the most recent change of -$380.00 thousand (-9.09%) on September 30, 2024. Over the past year, it has increased by +$2.09 million (+31.43%). RXRX quarterly CFI is now -103.18% below its all-time high of $143.30 million, reached on March 31, 2022.RXRX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RXRX TTM CFI
-$17.89 M
-$4.21 M-30.83%
30 September 2024
Summary:
As of January 23, 2025, RXRX TTM cash flow from investing activities is -$17.89 million, with the most recent change of -$4.21 million (-30.83%) on September 30, 2024. Over the past year, it has dropped by -$6.34 million (-54.97%). RXRX TTM CFI is now -109.25% below its all-time high of $193.25 million, reached on December 31, 2022.RXRX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RXRX Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -105.3% | +31.4% | -55.0% |
| 3 y3 years | -17.0% | +42.8% | -109.3% |
| 5 y5 years | -161.6% | +42.8% | -109.3% |
RXRX Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -105.3% | +96.2% | -103.2% | +91.3% | -109.3% | +93.4% |
| 5 y | 5-year | -105.3% | +96.2% | -103.2% | +97.7% | -109.3% | +93.4% |
| alltime | all time | -105.3% | +96.2% | -103.2% | +97.7% | -109.3% | +93.4% |
Recursion Pharmaceuticals Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$4.56 M(+9.1%) | -$17.89 M(+30.8%) |
| June 2024 | - | -$4.18 M(-37.1%) | -$13.67 M(+18.4%) |
| Mar 2024 | - | -$6.65 M(+167.4%) | -$11.54 M(+12.8%) |
| Dec 2023 | -$10.23 M(-105.3%) | -$2.49 M(+617.0%) | -$10.23 M(-34.9%) |
| Sept 2023 | - | -$347.00 K(-83.1%) | -$15.72 M(-141.8%) |
| June 2023 | - | -$2.05 M(-61.6%) | $37.61 M(-15.7%) |
| Mar 2023 | - | -$5.34 M(-33.1%) | $44.60 M(-76.9%) |
| Dec 2022 | $193.25 M | -$7.98 M(-115.1%) | $193.25 M(+29.7%) |
| Sept 2022 | - | $52.98 M(+972.6%) | $148.99 M(-252.2%) |
| June 2022 | - | $4.94 M(-96.6%) | -$97.87 M(-10.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $143.30 M(-374.3%) | -$109.02 M(-59.9%) |
| Dec 2021 | -$271.74 M(+3009.2%) | -$52.24 M(-73.1%) | -$271.74 M(+21.3%) |
| Sept 2021 | - | -$193.87 M(+3020.9%) | -$224.09 M(+566.0%) |
| June 2021 | - | -$6.21 M(-68.0%) | -$33.65 M(+22.5%) |
| Mar 2021 | - | -$19.42 M(+322.9%) | -$27.47 M(+214.3%) |
| Dec 2020 | -$8.74 M(+123.5%) | - | - |
| Dec 2020 | - | -$4.59 M(+34.0%) | -$8.74 M(+110.7%) |
| Sept 2020 | - | -$3.43 M(+8684.6%) | -$4.15 M(+473.9%) |
| June 2020 | - | -$39.00 K(-94.3%) | -$723.00 K(+5.7%) |
| Mar 2020 | - | -$684.00 K | -$684.00 K |
| Dec 2019 | -$3.91 M | - | - |
FAQ
- What is Recursion Pharmaceuticals annual cash flow from investing activities?
- What is the all time high annual CFI for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual CFI year-on-year change?
- What is Recursion Pharmaceuticals quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly CFI year-on-year change?
- What is Recursion Pharmaceuticals TTM cash flow from investing activities?
- What is the all time high TTM CFI for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals TTM CFI year-on-year change?
What is Recursion Pharmaceuticals annual cash flow from investing activities?
The current annual CFI of RXRX is -$10.23 M
What is the all time high annual CFI for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual cash flow from investing activities is $193.25 M
What is Recursion Pharmaceuticals annual CFI year-on-year change?
Over the past year, RXRX annual cash flow from investing activities has changed by -$203.48 M (-105.29%)
What is Recursion Pharmaceuticals quarterly cash flow from investing activities?
The current quarterly CFI of RXRX is -$4.56 M
What is the all time high quarterly CFI for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly cash flow from investing activities is $143.30 M
What is Recursion Pharmaceuticals quarterly CFI year-on-year change?
Over the past year, RXRX quarterly cash flow from investing activities has changed by +$2.09 M (+31.43%)
What is Recursion Pharmaceuticals TTM cash flow from investing activities?
The current TTM CFI of RXRX is -$17.89 M
What is the all time high TTM CFI for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high TTM cash flow from investing activities is $193.25 M
What is Recursion Pharmaceuticals TTM CFI year-on-year change?
Over the past year, RXRX TTM cash flow from investing activities has changed by -$6.34 M (-54.97%)